Dateline City:
WHITEHOUSE STATION, N.J. & LONDON
WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and AstraZeneca (NYSE: AZN) today announced a worldwide licensing
agreement for Mercks oral small molecule inhibitor of WEE1 kinase
(MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical
studies in combination with standard-of-care therapies for the treatment
of patients with certain types of ovarian cancer.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more